In this study, we want to determine the safety of the combination of pevonedistat, azacitidine and venetoclax for acute myelogenous leukemia. We will also evaluate how well this combination works in patients with AML. Everyone in this study will receive pevonedistat, azacitidine and venetoclax.
The study hypothesis is that the combination of pevonedistat, azacitidine, and venetoclax will be effective, safe, and well tolerated in patients with AML.
OPEN TO ACCRUAL